Pharming is paying $66.1 million to acquire Swedish biotech Abliva and its phase 2-stage med that the Dutch drugmaker believes has blockbuster potential with a type of mitochondrial disease.

Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The firm offers RUCONEST, which is a ...

6 analysts have expressed a variety of opinions on Pharming PHAR over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table provides a quick overview of ...

Leiden, the Netherlands, December 15, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) today announced a recommended public cash offer to ...

Jefferies initiated coverage of Pharming (PHAR) with a Buy rating and $14 price target The firm believes the market is either underappreciating the Joenja opportunity treating rare disease ...

Pharming has agreed a deal to sell a recently awarded priority review voucher (PRV) to Novartis for around $21 million - well below the market rate. The price of PRVs, which can be used to shorten ...

On Monday, Jefferies began coverage on shares of NASDAQ:PHAR, Pharming Group, with a positive outlook, assigning the stock a Buy rating and setting a price target of $14.00. The pharmaceutical ...

The conference call presentation is available on the pharming website from 14:00 CET on December 16, 2024 A transcript will be made available on the pharming website in the days following the call.